<DOC>
	<DOCNO>NCT02890953</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety single intraventricular administration Pneumostem® treatment Intraventricular hemorrhage ( IVH ) high-risk premature infant compare Pneumostem-treated group control group .</brief_summary>
	<brief_title>Efficacy Safety Pneumostem® IVH Premature Infants ( Phase 2a )</brief_title>
	<detailed_description />
	<criteria>IVH grade 34 age : within postnatal day 28 gestational age : 23 &lt; 34 week Patient severe congenital abnormality Patient antenatal brain hemorrhage Patient asphyxia Hypoxic ischemic encepalophathy Patient chromosome anomaly ( i.e . Edward syndrome , Patau syndrome , Down syndrome , etc ) severe congenital malformation ( Hydrocephalus , Encephalocele , etc ) Patient concurrent severe congenital infection ( i.e . Herpes , Toxoplasmosis , Rubella , Syphilis , AIDS , etc ) Patient withCRP &gt; 30 mg/dL ; Severe sepsis shock Patient severe intracranial hemorrhage ≥ grade 3 4 Patient history participate clinical study Patient consider inappropriate participate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>28 Days</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>